Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic Tests

Domain:

healthcare

Record type:

paper

Creator:

E. E. D. Q.

Publisher:

Ame

Host:

Xpert MTB/RIF rapidly detects resistance to rifampicin (RR); however, this test misses I491F-RR conferring the rpoB mutation, common in southern Africa. In addition, Xpert MTB/RIF does not distinguish between viable and dead Mycobacterium tuberculosis (MTB).

Visit

doi.org

Licenses

https://creativecommons.org/licenses/by/4.0/https://journals.asm.org/non-commercial-tdm-license

Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres

Non-sputum-based diagnostic tests are necessary to enable tuberculosis (TB) diagnosis and monitoring

Nanopore sequencing for <i>Mycobacterium tuberculosis</i> drug susceptibility testing and outbreak investigation

Abstract Background

Molecular Characterization and Drug Resistance Testing of <i>Mycobacterium tuberculosis</i> Isolates from Chad

ABSTRACT The molecular characterizations of the first 40 Mycob

Targeted genome sequencing for tuberculosis drug susceptibility testing in South Africa: A proposed diagnostic pipeline

In July 2023, the World Health Organization (WHO) began recommending targeted next-generation sequen

Diagnostic accuracy of Truenat Tuberculosis and Rifampicin-Resistance assays in Addis Ababa, Ethiopia

Background Rapid and sensitive Tuberculosis (TB) diagnosis closer to patients is a key global TB c

Rifampicin resistance patterns and dynamics of tuberculosis and drug-resistant tuberculosis in Enugu, South Eastern Nigeria

Introduction: Tuberculosis (TB) continues to be a public health problem globally. The burden is furt